IL139672A - Glucocorticoid receptor antagonists for the tretment of dementia - Google Patents

Glucocorticoid receptor antagonists for the tretment of dementia

Info

Publication number
IL139672A
IL139672A IL13967298A IL13967298A IL139672A IL 139672 A IL139672 A IL 139672A IL 13967298 A IL13967298 A IL 13967298A IL 13967298 A IL13967298 A IL 13967298A IL 139672 A IL139672 A IL 139672A
Authority
IL
Israel
Prior art keywords
dementia
glucocorticoid receptor
receptor antagonist
tretment
receptor antagonists
Prior art date
Application number
IL13967298A
Other languages
English (en)
Other versions
IL139672A0 (en
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IL139672A0 publication Critical patent/IL139672A0/xx
Publication of IL139672A publication Critical patent/IL139672A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
IL13967298A 1998-05-15 1998-10-05 Glucocorticoid receptor antagonists for the tretment of dementia IL139672A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8570398P 1998-05-15 1998-05-15
PCT/US1998/020908 WO1999059596A1 (en) 1998-05-15 1998-10-05 Glucocorticoid receptor antagonists for the treatment of dementia

Publications (2)

Publication Number Publication Date
IL139672A0 IL139672A0 (en) 2002-02-10
IL139672A true IL139672A (en) 2005-11-20

Family

ID=22193399

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13967298A IL139672A (en) 1998-05-15 1998-10-05 Glucocorticoid receptor antagonists for the tretment of dementia

Country Status (13)

Country Link
US (1) US6369046B1 (zh)
EP (1) EP1076562B1 (zh)
JP (3) JP2003505336A (zh)
KR (1) KR20010043630A (zh)
CN (1) CN1130200C (zh)
AT (1) ATE317699T1 (zh)
AU (1) AU756818B2 (zh)
CA (1) CA2328411C (zh)
DE (1) DE69833502T2 (zh)
HK (1) HK1032535A1 (zh)
IL (1) IL139672A (zh)
NZ (1) NZ507449A (zh)
WO (1) WO1999059596A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
EP1237476A1 (en) * 1999-12-02 2002-09-11 The General Hospital Corporation Method and apparatus for measuring indices of brain activity
US20010046470A1 (en) * 2000-05-10 2001-11-29 Kieko Morita Diagnoses and treatment of disorders using an alternative glucose pathway
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
JP2005512949A (ja) * 2001-05-04 2005-05-12 コーセプト セラピューティクス， インコーポレイテッド グルココルチコイドレセプターに特異的なアンタゴニストを使用して、せん妄を処置する方法
CN1853722A (zh) 2001-07-23 2006-11-01 科塞普特治疗公司 预防由抗精神病药物引起的体重增加的方法
IL160649A0 (en) * 2001-08-31 2004-07-25 Corcept Therapeutics Inc Methods for inhibiting cognitive deterioration in adults with down syndrome
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
EP1534299A4 (en) * 2002-07-02 2007-04-11 Corcept Therapeutics Inc METHOD FOR TREATING PSYCHOSIS IN CONNECTION WITH INTERFERON-ALPHA THERAPY
FR2850022B1 (fr) * 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
US7473903B2 (en) * 2003-02-12 2009-01-06 General Electric Company Method and apparatus for deposited hermetic cover for digital X-ray panel
EP3753561A1 (en) * 2005-04-05 2020-12-23 Yale University Glutamate modulating agents in the treatment of mental disorders
CA2673386A1 (en) * 2006-12-22 2008-07-03 Washington University High performance imaging system for diffuse optical tomography and associated method of use
US9480425B2 (en) * 2008-04-17 2016-11-01 Washington University Task-less optical mapping of dynamic brain function using resting state functional connectivity
AU2010324527A1 (en) * 2009-11-24 2012-07-19 Commonwealth Scientific And Industrial Research Organisation Methods, kits and reagents for diagnosing, aiding diagnosis and/or monitoring progression of a neurological disorder
WO2011150209A1 (en) * 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
WO2015187988A1 (en) * 2014-06-04 2015-12-10 Intellimedix Composition and methods of treating epilepsy and/or epilepsy-related disorders
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
US10261310B2 (en) 2016-06-27 2019-04-16 Amazon Technologies, Inc. Amorphous silicon layer as optical filter for thin film transistor channel
UA128573C2 (uk) 2019-12-11 2024-08-14 Корсепт Терапьютікс Інкорпорейтед Способи лікування підвищення маси тіла, індукованого антипсихотичними засобами, за допомогою мірикориланту
US20240066025A1 (en) * 2022-07-07 2024-02-29 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US5348729A (en) 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
FR2696934B1 (fr) 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
DE69737791D1 (de) 1996-04-09 2007-07-19 Univ Edinburgh Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen

Also Published As

Publication number Publication date
KR20010043630A (ko) 2001-05-25
AU9683398A (en) 1999-12-06
NZ507449A (en) 2003-08-29
CN1292701A (zh) 2001-04-25
JP2003505336A (ja) 2003-02-12
EP1076562B1 (en) 2006-02-15
CA2328411A1 (en) 1999-11-25
CA2328411C (en) 2008-12-16
CN1130200C (zh) 2003-12-10
DE69833502D1 (de) 2006-04-20
AU756818B2 (en) 2003-01-23
HK1032535A1 (en) 2001-07-27
US6369046B1 (en) 2002-04-09
IL139672A0 (en) 2002-02-10
DE69833502T2 (de) 2006-09-28
JP2009051864A (ja) 2009-03-12
ATE317699T1 (de) 2006-03-15
JP2009185067A (ja) 2009-08-20
WO1999059596A1 (en) 1999-11-25
EP1076562A1 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
IL139672A (en) Glucocorticoid receptor antagonists for the tretment of dementia
CY1108562T1 (el) Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
CA2302586A1 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
HK1068783A1 (en) Methods for increasing the therapeutic response to electroconvulsive therapy ("ect")
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
IL160649A0 (en) Methods for inhibiting cognitive deterioration in adults with down syndrome
PL369630A1 (en) Use of a h1 antagonist and rimexolone as a safe steroid to treat rhinitis
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
WO2004069202A3 (en) Antiglucocorticoids for the treatment of postpartum psychosis
IL158744A0 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
EP1726307A3 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
AU2002219192A1 (en) Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
DK1165184T3 (da) Estrogenreceptor-beta antagonisme og knoglesygdomme
WO2002020526A3 (en) Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
IL123536A0 (en) 5-HT3 Receptor antagonists for dyskinesia

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees